OR WAIT null SECS
© 2021 MJH Life Sciences and Rheumatology Network. All rights reserved.
© 2021 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
July 30, 2021
July 29, 2021
July 28, 2021
Read the most up-to-date information about the latest developments in psoriatic arthritis
The impact of psoriatic arthritis on patients’ quality of life and importance of an early, accurate diagnosis.
Test your knowledge of RA with this quiz
Learn more about the latest developments in rheumatoid arthritis
While prevention of atherosclerotic cardiovascular disease (ASCVD) in patients with rheumatoid arthritis (RA) is advocated by recent recommendations, ASCVD prevention in patients with RA was underwhelming, according to an international audit.
July 27, 2021
Roy Fleischmann, MD, discusses the recent Pfizer press release touching upon the safety of JAK inhibitors. He explains the recent scrutiny of JAKs, the concerns some rheumatologists have in regard to JAK inhibitors, and his personal opinions on prescribing JAK inhibiting drugs to his patients.
Guselkumab, an interleukin-23p19-subunit inhibitor, led to clinically significant and sustained improvements in fatigue through 1 year in patients with active psoriatic arthritis.
July 26, 2021
Patients with systemic lupus erythematosus presented more cardiovascular autonomic neuropathy, along with impaired health-related quality of life and parasympathetic function, when compared with a control cohort.
July 23, 2021
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 23, 2021.
Catch up on Rheumatology Network's most recent highlights in psoriatic arthritis news.
July 22, 2021
The painTRAINER program included 8 weekly modules, in addition to coping skill activities, in which investigators measured outcomes including the Pain Catastrophizing Scale, pain interference, physical function, anxiety and depression, fatigue, and sleep disturbances.
July 21, 2021
Treat-to-target remains a key strategy for the treatment of rheumatoid arthritis. However, some changes to the recommendations were made in the 2021 American College of Rheumatology Guidelines on the Management of Rheumatoid Arthritis.
Check your knowledge on how to approach a treat-to-target strategy with this quiz.
July 19, 2021
Investigators analyzed the effect of biologic therapies in order to determine the effectiveness of this first-line biologic approach in treating systemic juvenile idiopathic arthritis (sJIA) and reducing the exposure of glucocorticoids, a driver of morbidity in this patient population.
July 16, 2021
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 16, 2021.